Human papillomavirus and non-muscle invasive urothelial bladder cancer: Potential relationship from a pilot study

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 485-489

  Cai, Tommaso ^a   Mazzoli, Sandra ^b   Meacci, Francesca ^b   Nesi, Gabriella ^c   Geppetti, Pierangelo ^c   Malossini, Gianni ^a   Bartoletti, Riccardo ^c  

^a SANTA CHIARA HOSPITAL   (Italy)

^b Santa Maria Annunziata Hospital   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bladder cancer; Human papillomavirus; Urothelial carcinoma

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; URINALYSIS; WART VIRUS;

AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CARCINOMA; CASE-CONTROL STUDIES; DNA, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; RISK FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 78651352365     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1083     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Witjes JA: Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49: 790-797, 2006.
3. Jiménez Pacheco A, Martínez Torres JI, Pareja Vilchez M, et al: Statistical analysis of the influence of the virus of papilloma human in the development of the vesical carcinoma. Actas Urol Esp 31: 469-476, 2007.
4. Ozols RF, Herbst RS, Colson YL, et al: Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 25: 146-162, 2007.
5. Zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384: 260-265, 2009.
6. Ciotti M, Paba P, Bonifacio D, Di Bonito L, Benedetto A and Favalli C: Single or multiple HPV types in cervical cancer and associated metastases. Oncol Rep 15: 143-148, 2006.
7. Kraus I, Molden T, Holm R, et al: Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33 and 45 in the majority of cervical carcinomas. J Clin Microbiol 44: 1310-1317, 2006.
8. Zhang G, Sun L, Li Z, et al: HPV-16E6 can induce multiple site phosphorylation of p53. Oncol Rep 21: 371-377, 2009.
9. Moonen PM, Bakkers JM, Kiemeney LA, Schalken JA, Melchers WJ and Witjes JA: Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 52: 464-469, 2007.
10. Gutiérrez J, Jiménez A, De Dios Luna J, Soto MJ and Sorlózano A: Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus. J Urol 176 (6 Pt 1): 2474-2481, 2006.
11. Mazzoli S, Cai T, Rupealta V, et al: Interleukin 8 and anti-chlamydia trachomatis mucosal IgA as urogenital immunologic marker in patients with C. trachomatis prostatic infection. Eur Urol 51: 1385-1393, 2007.
12. Cai T, Mazzoli S, Mondaini N and Bartoletti R: Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay, et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 52: 464-469, 2007. Author reply, Eur Urol 53: 858-859, 2008.
13. Saslow D, Castle PE, Cox JT, et al: American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57: 7-28, 2007.
14. Tekin MI, Tuncer S, Aki FT, Bilen CY, Aygün C and Ozen H: Human papillomavirus associated with bladder carcinoma? Analysis by polymerase chain reaction. Int J Urol 6: 184-186, 1999.
15. Schifmann MH: Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol 186: 55-81, 1994. (Pubitemid 24099085)
16. Lopez-Beltran A, Escudero AL, Vicioso L, Munoz E and Carrasco JC: Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br J Cancer 73: 124-127, 1996. (Pubitemid 26026273)
17. Furihata M, Inoue K, Ohtsuki Y, Hashimoto H, Terao N and Fujita Y: High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 53: 4823-4827, 1993. (Pubitemid 23326173)
18. Tenti P, Zappatore R, Romagnoli S, et al: p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters. J Pathol 178: 65-70, 1996. (Pubitemid 26052082)
19. Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179: 175-183, 2002. (Pubitemid 34215109)
20. Barghi MR, Hajimohammadmehdiarbab A, Hosseini Moghaddam SMM and Kazemi B: Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis 5: 102-107, 2005. (Pubitemid 41662740)